A software company can look healthy from the outside and still have a revenue problem.
The dashboard says the pipeline is growing. Quarterly forecasts suggest targets are within reach. Customer numbers appear stable. A few months pass, and suddenly growth slows, projections fall short, and investors start pressing for answers.
What happened?
In many cases, the answer is not a sudden market shift or a failed product strategy. The problem has been sitting inside the go-to-market organization all along. It simply went unnoticed.
Revenue leakage doesn’t wave a red flag. You won’t find it called out in a financial statement or see it headline a board meeting. Most of the time, it’s hidden in all the little stuff: closing deals takes too long, sales chase leads that were never qualified, forecasts miss the mark, expansion plans fizzle, and salespeople waste effort in the wrong places.
If you look at these things one by one, they might not seem like a big deal. Stack them together, though, and they can take a serious bite out of growth and company value.
For private equity investors and revenue leaders, uncovering those hidden weaknesses has become increasingly important. That is where the GTM Health Check comes in.
Beyond Revenue Headlines
When investors consider an acquisition, they dive deep into the numbers, the market, the product, and how the company stacks up against competitors. All of this matters. But even sharp analysis can miss one thing: how efficiently the company actually turns opportunity into revenue. A business can post impressive growth numbers while operating with a commercial engine that is far less effective than it appears.
One operating partner recently described the challenge this way: “The numbers told us the company was growing. The data underneath told a different story.”
The sales team had built a large pipeline, but many opportunities had been sitting untouched for months. Forecast accuracy was inconsistent. Customer expansion efforts varied widely between account managers. None of those issues appeared obvious in headline metrics, yet all of them affected future performance.
The GTM Health Check is designed to uncover those realities.
Conducted over roughly 30 days, the assessment provides a detailed review of the company’s go-to-market operation. Rather than focusing solely on outcomes, it examines the mechanisms that drive those outcomes.
The goal is simple: identify where revenue is being lost and determine how much value can be recovered.
Revenue Leakage Starts Earlier Than Most Companies Think
When executives discuss revenue leakage, customer churn is often the first topic mentioned.
Churn is definitely important. It cuts straight into recurring revenue and future growth. But focusing only on churn often misses the bigger picture.
Some of the most damaging revenue leaks occur long before a customer ever signs a contract.
A sales team brings in plenty of leads but can’t seem to convert them. Another company loses deals at the last minute, mostly because they weren’t properly qualified from day one. And then there are those relying on CRM systems filled with incomplete, outdated, or flat-out wrong data.
The result is a distorted view of performance.
Leaders believe they have sufficient pipeline coverage when they do not. Forecasts appear reliable until quarter-end, when significant gaps emerge. Growth targets are established on assumptions that do not align with commercial reality.
None of these issues happens overnight. They develop gradually, often hidden behind encouraging top-line numbers.
What the Health Check Actually Examines
A comprehensive GTM Health Check looks at the whole revenue system, not just the parts that show up in a board pack.
It starts with pipeline quality: are the right opportunities moving through the funnel? Does the pipeline genuinely support the targets ahead, or is it wishful thinking? From there it moves to CRM integrity. Most teams depend on sales and customer data, but messy input, duplicate records, and inconsistent reporting undermine reliability at every level above the rep.
Next up is conversion performance, stage by stage. Even small breakdowns along the way eventually add up to real revenue losses.
The Health Check goes further, examining team structure, territory design, management layers, sales capacity, how customer success fits into the broader motion, and the compensation model. Each of these shapes how well the commercial engine actually runs.
Forecasting gets special attention. Boards and investors need hard forecasts to make calls about hiring, spending, and bigger strategies. Bad forecasting destroys confidence.
Scope discipline matters here. The goal isn’t a laundry list of every conceivable issue; it’s identifying the handful of critical breakdowns that are actually dragging down growth.
A Tool for Due Diligence and Post-Close Planning
One reason the GTM Health Check has gained traction among private equity firms is its flexibility.
Before a transaction closes, it serves as a due diligence tool. Investors gain a clearer understanding of commercial risks and growth opportunities that may not emerge through traditional financial analysis.
After an acquisition, the same findings become a roadmap for action.
The first hundred days following a deal are often decisive. Investors want momentum. Management teams need clarity. Everyone is trying to determine which initiatives deserve immediate attention.
When companies skip a real assessment, they end up chasing too many priorities at once, spreading resources thin and going in circles.
A structured GTM Health Check clears the fog. It ranks everything by business impact, so leadership can zero in on what matters and move the needle for real.
Turning Insight Into Enterprise Value
Perhaps the most valuable aspect of the process is its emphasis on quantification.
Finding problems is relatively easy. Measuring their financial consequences is far more useful.
When teams see hard data on lost revenue, whether it’s weak pipeline management, poor conversions, bad forecasting, or retention issues, they stop guessing and start making decisions that stick.
That shift can be powerful.
Across more than 30 GTM Health Checks Habenae has run for private equity-backed B2B technology companies in North America and EMEA, one truth keeps repeating: significant growth opportunities often exist inside the business long before they require new products, new markets, or larger budgets.
That’s where real differentiation lives. The top-performing companies aren’t just the ones with the fattest pipeline or the boldest forecasts. They’re the teams that find the leaks, fix them fast, and build repeatable systems that deliver growth they can count on quarter after quarter. In today’s software market, that discipline is no longer a competitive advantage. It is becoming a requirement.
Habenae’s GTM Health Check is built specifically for this moment in the deal lifecycle — delivered in 30 days, with findings mapped directly to the investment thesis and ready for the first board meeting after close. For operating partners weighing a due diligence read or a 100-day plan, that is usually where the conversation should start.
